Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck area, progressive respiratory distress, and dysphagia. The article describes a clinical case of a response of unresectable, BRAF -negative, PD-L1-positive (programmed death-ligand 1) anaplastic thyroid cancer to immunotherapy with pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Vontlaya et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: